Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program
ANNOUNCEMENT NO. 176 – 15 AUGUST 2024 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com
Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension means that the research group at the Karolinska Institutet, led by Professor Birgitta Henriques Normark, continues to be part of the successful collaboration between the KI, the Swedish University of Agricultural Sciences (SLU) and Intervacc. This collaboration has led to the development of Strangvac, a vaccine against the streptococcal infection
